VANCOUVER, BC and PHOENIX, AZ--(Marketwired - Aug 29, 2013) - Eternity Healthcare Inc. (
The Company plans to use the proceeds of this financing to implement a strong product marketing program, for the sales and commercialization of its products to further business development.
"We continue to progress in our business development strategy we see tremendous growth potential in our product sales channels and have fulfilled the need to maintain sufficient funds to achieve such goals without making an un-necessary dilution to shareholders equity," said Dr. Salari, President & CEO of Eternity Healthcare.
About Eternity Healthcare Inc. (
Eternity Healthcare is a biopharmaceutical company with technologies in drug delivery, specialty pharmaceuticals and medical devices. We are currently focusing on the development of new subcutaneous formulation of otherwise intramuscular injectable drugs and needle-free injection systems. Our products are sold to healthcare professionals, for use in physicians' offices, pharmacies, and to consumers directly. Our products are all manufactured under strictly compliant with GMP, ISO 9001 and ISO 13485 procedures, with special emphasis on quality control at each and every stage of production. More information on Eternity Healthcare Inc. can be found on the website. www.eternityhealthcare.com
Safe Harbor Statement
This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as ETAH or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.